"10.1371_journal.pone.0038369","plos one","2012-07-16T00:00:00Z","Kerstin Höhne; Stephan J Schließmann; Andreas Kirschbaum; Till Plönes; Joachim Müller-Quernheim; Hermann Tenor; Gernot Zissel","Division of Internal Medicine, Department of Pneumology, University Medical Centre, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany; Division of Surgery, Department of Thoracic Surgery, University Medical Centre, Freiburg, Germany; Nycomed GmbH Global Discovery, Nycomed GmbH, Konstanz, Germany","Conceived and designed the experiments: KH JMQ HT GZ. Performed the experiments: KH HT. Analyzed the data: KH SJS GZ. Contributed reagents/materials/analysis tools: KH SJS AK TP. Wrote the paper: KH SJS GZ.","This study was supported by a research grant from Nycomed GmbH, Konstanz, Germany. HT is an employee of Nycomed GmbH. GZ is a PLoS ONE Editorial Board member. Roflumilast is the effective component of “Daxas” which is sold by Nycomed for COPD treatment to minimize exacerbations. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","07","Kerstin Höhne","KH",7,TRUE,4,2,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
